Navigation Links
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
Date:4/29/2013

NEW YORK, April 29, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of PROLOR Biotech, Inc. ("PROLOR" or the "Company") (NYSE MKT: PBTH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to OPKO Health, Inc. ("OPKO") (NYSE: OPK).

(Logo:  http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

Click here to learn more about the investigation http://zlk.9nl.com/prolor-biotech-pbth/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, PROLOR shareholders may elect to receive 0.9951 shares of OPKO for each share of PROLOR they own, representing a value of approximately $7.025 per share. The transaction has a total approximate value of $480 million. The investigation concerns whether the PROLOR Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the transaction, and whether OPKO is underpaying for PROLOR stock, thus unlawfully harming PROLOR stockholders. In particular, at least one analyst set a price target for PROLOR  stock at $12.00 per share.

If you own common stock in PROLOR and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/prolor-biotech-pbth/

Levi & Korsinsky is a national firm with offices in New York, New Jersey and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
2. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
3. Hadasit Bio-Holdings CEO Letter to Shareholders
4. Medifirst Solutions, Inc. Announces Further Update To Shareholders
5. Letter from Alliqua CEO, Dave Johnston, to Shareholders
6. TPI to Hold 2012 Shareholder Annual Meeting on May 8, 2013 In New York City
7. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
8. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
9. Amarantus BioSciences Issues CEO Letter to Shareholders
10. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
11. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... ... August 09, 2017 , ... As a ... reach its ideal customers with the right message. Their effective, cutting-edge inbound marketing ... company, we realize how crucial the agriculture industry is,” said David Phelps, chief ...
(Date:8/10/2017)... ... August 09, 2017 , ... Each year in the United States more than ... live an independent lifestyle and, even worse, the one-year mortality rate is high, ranging ... the University of California Davis Medical Center (Sacramento) and Second Xiangya Hospital of the ...
(Date:8/10/2017)... ... August 10, 2017 , ... DrugDev and the Society ... to demonstrate how Good Clinical Practice (GCP) can be used throughout the site activation ... will discuss the importance of GCP compliance, how sites are affected by GCP during ...
(Date:8/10/2017)... , ... August 10, 2017 , ... ... the AptaFluor SAH Methyltransferase Assay , an enabling new high throughput screening ... pathways that drive cancer and other debilitating diseases. , Chemical modification of gene ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
Breaking Biology News(10 mins):